Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$230.22M-23.79%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kimberly A. Rivers
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 5,000
- Beta
- 1.92
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 0.24
Financials
TRLV has only 6 quarterly periods on file — the charts below show the full history available.
Revenue
$230.22M-23.8%Net Income
$869.0KEBITDA
$59.52M-39.5%Free Cash Flow
$45.43M-34.6%EPS (diluted)
$0.00Shares Outstanding (diluted)
200.61M+4.9%Operating Expenses
$87.84MCash & Debt
$326.69MReturn of Capital
$1.41MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.18B | $-116.38M | $-0.61 |
Valuation
TRLVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-36.00%Social Signal Score
Mentions (7)
- Newsprnewswire.com·6d ago·Negative
Trulieve Announces Preliminary Addition to the Russell 2000® and 3000® Indices TALLAHASSEE, Fla., Nov. 16, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced that the company is set to join to the Russell 2000® and 3000® Indices as part of the semi-annual Russell Indexes reconstitution, according to a preliminary list published by FTSE Russell on Friday, November 13, 2026.
View source ↗ - Newsprnewswire.com·11d ago·Neutral
Trulieve Announces November 2026 Event Participation TALLAHASSEE, Fla., Nov. 11, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced planned event participation in November.
View source ↗ - Newsprnewswire.com·17d ago·Neutral
…g state licensed medical marijuana to Schedule III under the Controlled Substances Act TALLAHASSEE, Fla., Nov. 5, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced its results for the quarter ended September 30, 2026.
View source ↗ - Newsprnewswire.com·46d ago·Negative
Trulieve Repays $65 Million Mortgage Strengthening Balance Sheet TALLAHASSEE, Fla., Oct. 7, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced the full repayment of an approximately $65 million mortgage notes payable secured by a cultivation site in Jefferson County, Florida, thereby reducing outstanding debt to approximately $225 million.
View source ↗ - Newsprnewswire.com·55d ago·Negative
…rida and Texas Perpetual Royalty-Free License Covers Alien Labs and Connected Brands TALLAHASSEE, Fla., Sept. 28, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S, today announced a licensing deal with Connected for the exclusive rights to genetics, trademarks, and proprietary know-how to produce and sell Alien Labs and Connected branded cannabis products in Florida and Texas.
View source ↗ - Newsseekingalpha.com·72d ago·Positive
…% rally. Rescheduling of medicinal cannabis to Schedule III eliminates punitive tax burdens, boosts cash flows, and enables greater R&D and financing flexibility for TRLV. TRLV is well-positioned for growth through Florida consolidation, expansion into Texas and Alabama, and potential upside from a $583M tax liability reversal.
View source ↗ - Newsprnewswire.com·103d ago·Negative
Trulieve Completes Redomicile from British Columbia to Delaware TALLAHASSEE, Fla., Aug. 11, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced the completion of its previously announced plan to redomicile Trulieve Cannabis Corp. from British Columbia, Canada to Delaware, United States.
View source ↗
Earnings
Thu, Feb 4(in 2 months)
Consensus estimate $0.02 per share
Typical surprise -65.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$0.09 vs $0.09miss
- Thu, Aug 6$-2.11 vs $0.06miss
- Thu, May 7$0.01 vs $-0.01beat
- Thu, Feb 26$-0.22 vs $-0.07miss
- Wed, Nov 5$-0.14 vs $-0.08miss
- Wed, Aug 6$-0.07 vs $-0.06miss
Estimates and results for TRLV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TRLV officers and directors.
- Bought
- —
- Sold
- $14.7m
0 trades
7 trades
- Rivers Kim A.sold
- Rivers Kim A.sold
- Rivers Kim A.sold
- Rivers Kim A.sold
- Rivers Kim A.sold
- Rivers Kim A.sold
- Rivers Kim A.sold
Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TRLV.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
